{"id":"W2804990894","doi":"10.3324/haematol.2017.171249","title":"Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study","year":2018,"lang":"en","type":"article","venue":"Haematologica","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Pfizer","keywords":"Bosutinib; Medicine; Cumulative incidence; Internal medicine; Nausea; Myeloid leukemia; Adverse effect; Imatinib; Gastroenterology; Rash; Mucositis; Oncology; Dasatinib; Surgery; Toxicity; Cohort","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005630155,0.0004741135,0.001569167,0.0001975694,0.0002557736,0.00001244871,0.0002511628,0.0002583883,0.001294321],"category_scores_gemma":[0.0005660324,0.0003696747,0.0002637836,0.0003314971,0.0007021684,0.00009815677,0.0002495567,0.0002795868,0.00002209384],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001196937,"about_ca_system_score_gemma":0.001742214,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000987876,"about_ca_topic_score_gemma":0.0002376446,"domain_scores_codex":[0.9966335,0.0001156995,0.001337929,0.000868134,0.0004073999,0.0006373165],"domain_scores_gemma":[0.9974207,0.0004010431,0.0007024599,0.0009550966,0.0002827166,0.0002380151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4588529,0.07794955,0.005193154,0.01029742,0.008958185,0.002756432,0.03636663,0.00007065897,0.1742135,0.003231179,0.02892915,0.1931812],"study_design_scores_gemma":[0.6422958,0.2312897,0.01615891,0.001327045,0.001931655,0.001132631,0.001215888,0.004224177,0.05491415,0.00009265947,0.04449631,0.0009210863],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933725,0.001252983,0.00009578971,0.0001864801,0.0001265918,0.003308564,0.0006356182,0.00008640571,0.0009350443],"genre_scores_gemma":[0.9966267,0.0001298898,0.001062453,0.00005154603,0.0003187094,0.0001132062,0.0002104118,0.0000479923,0.001439053],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1922601,"threshold_uncertainty_score":0.9998755,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03689671586753953,"score_gpt":0.344653472804586,"score_spread":0.3077567569370465,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}